Institutional investors hold a majority ownership of MYGN through the 137.28% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended March 2015, these large investors purchased a net $1.8 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
SCOPIA CAPITAL MANAGEMENT LLC Bought 1.6 Million shares of Myriad Genetics Inc
IRIDIAN ASSET MANAGEMENT LLC Bought 1.4 Million shares of Myriad Genetics Inc